Hi Reg
The key finding is that inflammation, which is seen in about 50% of these patients, is both a predictor of severe outcomes and a predictor of therapeutic benefit in response to rexlemestrocel. We met with the FDA very recently and had a very encouraging meeting under our existing RMAT designation to discuss the potential pathway to approval for patients with this devastating complication. And we expect to have FDA formal minutes in June -- later in March.
Any Idea what the last line means.?
Aloha
.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.63 |
Change
0.015(0.93%) |
Mkt cap ! $2.082B | |||
| Open | High | Low | Value | Volume |
| $1.63 | $1.67 | $1.61 | $6.975M | 4.265M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 707 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.64 | 7320 | 2 |
View Market Depth
| Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |